Trial Condition(s):

Hand Eczema

Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema

Bayer Identifier:

1401663

ClinicalTrials.gov Identifier:

NCT00488241

EudraCT Number:

Not Available

Study Completed

Trial Purpose

To show efficacy of Zarzenda in the treatment of hand eczema

Inclusion Criteria
- Mild to moderate hand eczema for at least 3 months
- At least 4 weeks have passed since use of systemic treatment for eczema
- At least 4 weeks have passed since any vaccination
- At least 1 week has passed since last topic treatment on hands with corticosteroids
- Agree to use adequate contraceptive method if of childbearing potential
- Willingness to avoid excessive exposure to sunlight and avoid skin irritants
Exclusion Criteria
- Pregnancy, breast feeding
- Severe excoriations on the hands
- Need for systemic treatment for atopic dermatitis
- Known sensitivity to Zarzenda and/or to extract of nut butyrospermum parkii (shea)
- Known immune deficiency
- Concomitant infection on hands

Trial Summary

Enrollment Goal
40
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Atopiclair (Zarzenda)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Intendis GmbH

Berlin, Germany

Status
Completed
 

Trial Design